Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Native peptides

ABSTRACT: Investigating the profile of normal urinary peptidome, and the peptidases involved in its generation is extremely important as it reflects the human normal physiology, and the incidence of any change can be used as an indicator for pathological processes occurred in vivo. Thus, in this study, we interested in the characterization of normal urinary peptidome as well as investigating the different catalytic enzymes which involved in urinary native peptide generation.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Tadashi Yamamoto

PROVIDER: PXD009972 | JPOST Repository | Thu May 31 00:00:00 BST 2018

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	NP03_HCDETD_01.raw	Raw
	NP03_HCDETD_02.raw	Raw
	NP04_HCDETD_01.raw	Raw
	NP04_HCDETD_02.raw	Raw
	NP05_HCDETD_01.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Characterization of the human urinary proteome and peptidome

Project description:Urine represents an ideal source of clinically relevant biomarkers since it contains a large number of proteins and low molecular weight peptides. Characterization of the normal urinary proteome and peptidome can serve as a reference for disease and can aid in biomarker discovery. Proteomic and peptidomic analysis of urine can also provide insight into normal physiology and disease pathology, especially for urogenital diseases. We developed an integrated proteomic and peptidomic analytical protocol for normal urine. We employed ultrafiltration to separate protein and peptide fractions, which were analyzed separately using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) on the Q-Exactive mass spectrometer. By analyzing six urines from healthy individuals, we identified 1754 proteins by proteomic analysis and 4543 endogenous peptides, arising from 566 proteins by peptidomic analysis. Overall, we identified 2091 non-redundant proteins by this integrated approach. In silico protease activity analysis indicated that metalloproteases are predominantly involved in the generation of the endogenous peptide signature. In addition, a number of proteins that were detected in normal urine have previously been implicated in various urological malignancies, including bladder cancer and renal cell carcinoma. Thus, this study can provide a reference for assessing alterations in cancer-specific biomarkers.

2016-07-12 | PXD003595 | Pride

Ppatens transcriptome

Project description:We studied peptide generation process in moss Physcomitrella patens. For this purpose, analysis of peptidome and transcriptome of two different life forms (gametophores and protonema) and also of protoplasts were made.

2014-04-22 | E-MTAB-1637 | biostudies-arrayexpress

Characterization of the human urinary proteome and peptidome

2016-10-21 | MSV000080263 | MassIVE

Exploring salivary peptidomic profiling of feline chronic gingivostomatitis using MALDI-TOF mass spectrometry and nanoLC-tandem mass spectrometry: Insights into viral infections and histopathology confirmed

Project description:Cats with feline chronic gingivostomatitis (FCGS) have moderate to severe pain. The cause might be related to insufficient immune response to oral antigenic stimulation. Salivary peptidome is an alternative method for investigating inflammatory protein mediators and the pathways involved in oral mucosal immune activation appear to be a promising avenue of research for FCGS therapy.

2025-06-05 | PXD052874 | JPOST Repository

Urinary exosomal long noncoding RNAs may be novel biomarkers for the diagnosis of clear cell renal cell carcinoma

Project description:Background: Renal cell carcinoma, which presents no significant clinical manifestations at early stages, is one of the few tumors with an increasing worldwide incidence. This malignancy cannot be directly detected by tumor markers in body fluid without information from imaging examinations. Approximately 30–40% of patients with kidney cancer exhibit distant metastasis at diagnosis, and their 5-year survival rate is much lower than that of patients with early-stage renal cell carcinoma. Thus, the early diagnosis of renal cell carcinoma is extremely important. The aim of this study was to investigate the utility of urinary exosomal long noncoding RNA (lncRNA) as a new potential diagnostic marker for renal cell carcinoma. Methods: Exosomes were isolated by ultracentrifugation from 50-ml urine samples from 10 patients with clear cell renal cell carcinoma and 10 matched healthy donors. Differentially expressed lncRNAs were analyzed by next-generation sequencing and further validated in kidney cancer cell lines, tissues and urinary exosomes. Then, we evaluated the sensitivity, specificity, clinical diagnostic value and stability of the selected lncRNAs. Results: The levels of lncRNAs NR_040448 and NR_033390 in urinary exosomes can likely indicate the presence of renal cell carcinoma. In addition, RNA protected by exosomes was stable enough to serve as a biomarker. Conclusion: Urinary exosomal lncRNA is a promising marker for the early diagnosis of renal cell carcinoma.

2019-01-23 | GSE125442 | GEO

Urinary PRM analysis of early type 1 diabetes

Project description:Chronic hyperglycemia is known to disrupt the proteolytic milieu, initiating compensatory and maladaptive pathways in the diabetic kidney. Such changes in intrarenal proteolysis can be captured in the urinary peptidome. We thus examined the urinary peptidomes of otherwise healthy youths with type 1 diabetes and their non-diabetic peers. This cross-sectional study included two separate cohorts for the discovery (N = 30) and initial validation (N = 30) of differential peptide excretion. Peptide bioactivity was predicted using PeptideRanker and subsequently verified in vitro. Proteasix and the Nephroseq database were used to identify putative proteases responsible for peptide generation and examine their expression in diabetic nephropathy. A total of 6550 urinary peptides were identified in the discovery analysis. Of the 15 differentially excreted peptides (P < 0.05), seven derived from a small region (589SGSVIDQSRVLNLGPITRK607) near the C-terminus of uromodulin. Excretion rates of five uromodulin peptides were validated using parallel reaction monitoring (P < 0.05). One of the validated peptides activated TLR4-dependent NFκB signalling, stimulated cytokine release, and enhanced neutrophil migration in vitro. In silico analyses identified several possible proteases such hepsin, cathepsin B, and meprin A to be responsible for generating these peptides. In summary, uromodulin processing in the kidney produces bioactive peptides, which may be differentially excreted in early diabetes.

2020-01-01 | PXD012389 | panorama

Comparison of WAT CD34+ vs LAF CD34+

Project description:A catalytic role has been proposed in neoplastic angiogenesis and cancer progression for bone marrow-derived endothelial progenitor cells (EPCs). However, in preclinical and clinical studies the quantitative role of marrow-derived EPCs in cancer vascularization was found to be extremely variable. Adipose tissue represents an attractive source of autologous adult stem cells due to its abundance and surgical accessibility. CD34+cells from Lipotransfer aspirates (LAs) of patients undergoing breast reconstruction after breast cancer surgery were compared with CD34+ cells from Leucapheresis of normal subjects.

2011-08-16 | GSE31415 | GEO

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104431 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

2019-10-24 | GSE104430 | GEO

Urine miRNA transcriptome of prostate cancer patients [Training cohort]

2019-10-24 | GSE104429 | GEO